EU clears AbbVie takeover of Allergan subject to conditions

BRUSSELS (Reuters) - The European Commission said on Friday it had approved U.S. drugmaker AbbVie's planned $63 billion (48.24 billion pounds) acquisition of Botox-maker Allergan , subject to conditions.The Commission, which oversees competition policy in the European Union, said its approval was conditional on the divestment of a product under development by Allergan to treat inflammatory bowel diseases."Our decision makes sure that the merger between AbbVie and Allergan will not disrupt the..